3 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
and securities litigation; system failures, unplanned events, or cyber incidents; the substantial number of shares subject to potential issuance associated
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
, potential product liability and securities litigation;
System failures, unplanned events, or cyber incidents;
The substantial number of shares subject
- Prev
- 1
- Next